Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of irinotecan liposomes in total neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2500105100Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of nanoliposomal irinotecan in rectal cancer (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Complete response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2500105100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105100.